Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care.
The discussion also explores the growing role of measurable residual disease…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.